Business Wire

The Estée Lauder Companies Announces Chris Good, Group President, North America to Retire After Exceptional Career

16.11.2021 15:00:00 EET | Business Wire | Press release

Share

Today, The Estée Lauder Companies (NYSE:EL) (“ELC”) announced that Chris Good, Group President, North America, after nearly 25 years with the company, has made the decision to retire effective June 30, 2022. The successor to Chris’ role will be announced shortly, and Chris will partner closely with this individual to support a smooth and successful transition.

“Chris is a visionary, global leader who is deeply admired at ELC and recognized across the beauty industry worldwide. With his extensive international background, Chris’ leadership agility and deep insights into our diverse markets and consumers around the world have made an indelible impact on our business,” said Fabrizio Freda, President and Chief Executive Officer. “Known for his extraordinary business acumen, ability to build high-performing teams, and his track record of achieving strong results in both nascent and established markets globally, Chris has exemplified a commitment to excellence.”

For the past five years, Chris led ELC’s North America business, a highly complex, competitive, and fast-evolving prestige beauty landscape. He oversaw the region’s pivotal retail and organizational transformation, establishing critical capabilities to drive growth and operational efficiencies.

Additionally, Chris elevated data analytics and insights to unlock new and granular opportunities across brands, consumers, and channels. His expertise in channel strategy has accelerated the online business and strengthened the region’s retail relationships, optimizing brick-and-mortar by prioritizing high-performing doors and specialty-multi, and driving brand-building distribution in freestanding stores and emerging channels through modernized omni-experiences.

Chris consistently transformed the business while running it – pivoting with agility and resilience to accelerate recovery in a dynamic environment, while navigating numerous headwinds in North America. Over the past year and a half, he collaborated with his leadership team to steer the region through the complexities of the COVID-19 pandemic, as well as broader macro and social issues, leading with the company’s values and the wellbeing of ELC’s people in mind.

Under Chris’ steady leadership, the North American business returned to growth in fiscal year 2021 and has continued its momentum into the first quarter of fiscal year 2022. To start the new fiscal year, North America delivered strong net sales growth with sales increases across every category. Chris and his leadership team have laid a healthy foundation for long-term, sustainable recovery and growth in North America.

Chris started at ELC in Clinique Marketing in the U.K. and Ireland in 1987. After a period away from the company, where Chris took on senior marketing executive and general management roles for Unilever across Europe, North America and Asia/Pacific, he returned in 2000, as General Manager/Regional Vice President for Clinique, Asia/Pacific, where he helped grow the China and Japan affiliates in their early days. In 2005, he was named General Manager of the recently-established Russian affiliate and in 2008, he became Senior Vice President, Central and Eastern Europe, Middle East, India, and Africa.

Chris was appointed Managing Director, U.K. and Ireland in 2012. While there, he helped pioneer the company’s successful evolution from a traditional department store model into a diversified omnichannel business, leading in brand-building channels such as e/m-commerce and specialty-multi. He was promoted to President, U.K. and Ireland in 2014, and during his tenure, the business generated consistent double-digit, compound annual sales growth and tripled online net sales.

“We are grateful for Chris’ tremendous contributions to our business, and the resolve and dedication he has demonstrated to push boundaries, invent the unexpected and bring the best to ELC and beyond. He has championed our company values and embodied our culture both in the Field and alongside his teams, continuously fueling collaboration and creativity,” said William P. Lauder, Executive Chairman. “Across our global ELC family and the wider industry, Chris has nurtured strong relationships and his hospitable nature, dynamic leadership, and deep retail expertise will be truly missed. On behalf of the company and the Lauder family, I would like to wish Chris the very best in his well-deserved retirement.”

About The Estée Lauder Companies Inc.

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers and sellers of quality skin care, makeup, fragrance and hair care products. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin Paris, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.

ELC-C
ELC-L

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investors: Rainey Mancini
rmancini@estee.com

Media: Jill Marvin
jimarvin@estee.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye